India has put a temporary hold on all major exports of Covishield, the AstraZeneca coronavirus vaccine made by the Serum Institute of India (SII), to meet demand at home as infections rise, two sources told Reuters.
The move will also affect supplies to the GAVI/WHO-backed COVAX vaccine-sharing facility through which more than 180 countries are expected to get doses, one of the sources said.
COVAX has so far received 17.7 million AstraZeneca doses from SII, of the 60.5 million doses India has shipped in total, and many countries are relying on the programme to immunise their citizens.
There has been no vaccine export from India since Thursday, the foreign ministry's website https://www.mea.gov.in/vaccine-supply.htm shows, as the country expands its own immunisation effort.
"Everything else has taken a backseat, for the time being at least," said one of the sources. Both sources had direct knowledge of the matter, but declined to be named as the discussions are not public.
"No exports, nothing till the time the India situation stabilises. The government won't take such a big chance at the moment when so many need to be vaccinated in India."
India's foreign ministry and SII, the world's biggest vaccine manufacturer, did not immediately reply to requests for comment.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU